OAM
ANIP icon

Origin Asset Management’s ANI Pharmaceuticals ANIP Stock Holding History

Origin Asset Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,203
Closed -$213K – 169
2016
Q3 		$213K Buy
+3,203
New +$200K 0.01% 148

Other funds holding ANIP

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Origin Asset Management's ANIP Position: Q4 2016 in Review

Origin Asset Management sold out of ANI Pharmaceuticals (ANIP) in Q4 2016, closing a stake of 3,203 shares — an estimated $213K sold.

Origin Asset Management first reported a position in ANIP in Q3 2016 and held it in 1 quarter. The position peaked at $213K in Q3 2016. 157 funds tracked by Wall St. Rank hold ANIP as of Q4 2016.

  • Origin Asset Management reported no remaining ANI Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Origin Asset Management sold 3,203 ANI Pharmaceuticals shares in Q4 2016, an estimated $213K.
  • Origin Asset Management first reported a position in ANI Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Origin Asset Management's ANI Pharmaceuticals position peaked at $213K in Q3 2016.
  • 157 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2016.

Based on Origin Asset Management's 13F filing for Q4 2016, filed 3 Mar 2017.